Silexion Therapeutics Ltd.
Silexion Therapeutics Ltd.
Your view on SLXNW
Overview
What the company does, where it operates, and who runs it.
About Silexion Therapeutics Ltd.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ilan Hadar
- Headquarters
- The Goldyne Savad Institute of Gene Therapy, Jerusalem, TA, IL
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ilan Hadar
- Headquarters
- The Goldyne Savad Institute of Gene Therapy, Jerusalem, TA, IL
Silexion Therapeutics LTD is a biopharmaceutical company focused on the discovery and development of RNA interference (RNAi)-based therapies and their delivery systems, specifically targeting aggressive solid tumors. The firm utilizes its proprietary LODER delivery platform for the treatment of these malignant growths.
Its pipeline features SiG12D-LODER, which has successfully completed preclinical investigations and an open-label Phase I clinical trial for pancreatic cancer.
Additionally, the company is advancing Prostate-LODER through preclinical studies for prostate cancer, and GBM-LODER, also in preclinical stages, to address Glioblastoma Multiforme, a severe primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Silexion Therapeutics Ltd. from FRC's valuation model, read against the market price. SLXNW last traded at $0.0043; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Silexion Therapeutics Ltd.. Starting points for Silexion Therapeutics Ltd.: EPS -$71.54, beta -0.27 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Silexion Therapeutics Ltd.. Silexion Therapeutics Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Silexion Therapeutics Ltd.. Trailing twelve-month EPS for Silexion Therapeutics Ltd. stands at -$71.54. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Earnings Estimate
| EPS | Current QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|
| Avg. estimate | -$170.40 | -$1,128.00 | -$441.60 |
| Low estimate | -$170.40 | -$1,128.00 | -$441.60 |
| High estimate | -$170.40 | -$1,128.00 | -$441.60 |
| No. of analysts | 1 | 1 | 1 |
| Year-ago EPS | -$23.851 | -$2,150.401 | — |
| Growth | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|
| Avg. estimate | $0.00 | $0.00 | $0.00 |
| Low estimate | $0.00 | $0.00 | $0.00 |
| High estimate | $0.00 | $0.00 | $0.00 |
| No. of analysts | 0 | 0 | 0 |
| Year-ago revenue | $0.00 | $0.00 | — |
| Growth | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 16, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Silexion Therapeutics Ltd.. Silexion Therapeutics Ltd. has reported as a listed company since 2024. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ACONAclarion, Inc.Medical - Healthcare Information Services$4M
- AKTXAkari Therapeutics, PlcBiotechnology$16M
- DRMADermata Therapeutics, Inc.Biotechnology$3M
- FOXOFOXO Technologies Inc.Medical - Care Facilities$8,997
- PIIIP3 Health Partners Inc.Medical - Care Facilities$9M
- PPBTPurple Biotech Ltd.Biotechnology$225,077
- REVBRevelation Biosciences, Inc.Biotechnology$2M
- SYRSSyros Pharmaceuticals, Inc.Biotechnology$21,464
More Biotechnology companies
- BPMUFBasilea Pharmaceutica AGOTC$871M
- BPTHBio-Path Holdings, Inc.OTC$554,529
- BPTSYBiophytis S.A.OTC$189,402
- BRAXFBraxia Scientific Corp.OTC$30,017
- BRCTFBioArctic AB (publ)OTC$3.4B
- BRIBFBrii Biosciences LimitedOTC$136M
- BRNSBarinthus Biotherapeutics plcNASDAQ$30M
- BRTXBioRestorative Therapies, Inc.NASDAQ$2M
- BRVEBraveheart Bio, Inc.NASDAQ$1.4B
- BSEMBioStem Technologies, Inc.OTC$20M
- BSSPBaseline Productions, Inc.OTC$74,377
- BTAIBioXcel Therapeutics, Inc.NASDAQ$2M
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Silexion Therapeutics Ltd., and how their positions are changing. At a $70,256 market value, institutional positions materially move Silexion Therapeutics Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Silexion Therapeutics Ltd. executives and directors. Shares of Silexion Therapeutics Ltd. have traded between $0.02 and $0.03 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Silexion Therapeutics Ltd.. Coverage tracks Silexion Therapeutics Ltd. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Silexion Therapeutics Ltd.